• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI Executive AssistantNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI Executive AssistantNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Helper
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees for your businessNEW
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SC 13G/A filed by Royalty Pharma plc (Amendment)

    2/9/23 11:06:35 AM ET
    $RPRX
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $RPRX alert in real time by email
    SC 13G/A 1 p23-0704sc13ga.htm ROYALTY PHARMA PLC

     

    SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549
     
    SCHEDULE 13G/A
     
    Under the Securities Exchange Act of 1934
    (Amendment No. 3)*
     

    Royalty Pharma plc

    (Name of Issuer)
     

    Class A Ordinary Shares, par value $0.0001 per share

    (Title of Class of Securities)
     

    G7709Q104

    (CUSIP Number)
     

    December 31, 2022

    (Date of Event Which Requires Filing of This Statement)
     
     
    Check the appropriate box to designate the rule pursuant to which this Schedule is filed:
     
    ¨ Rule 13d-1(b)
    ý Rule 13d-1(c)
    ¨ Rule 13d-1(d)
     
    (Page 1 of 10 Pages)

     

    ______________________________

    *The remainder of this cover page shall be filled out for a reporting person's initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.

    The information required in the remainder of this cover page shall not be deemed to be "filed" for the purpose of Section 18 of the Securities Exchange Act of 1934 ("Act") or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

     

     

     

     

     

     

    CUSIP No. G7709Q10413G/APage 2 of 10 Pages

     

    1

    NAME OF REPORTING PERSON

    Adage Capital Partners, L.P.

    2 CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP

    (a) ¨

    (b) ¨

    3 SEC USE ONLY
    4

    CITIZENSHIP OR PLACE OF ORGANIZATION

    Delaware

    NUMBER OF
    SHARES
    BENEFICIALLY
    OWNED BY
    EACH
    REPORTING
    PERSON WITH:
    5

    SOLE VOTING POWER

    0

    6

    SHARED VOTING POWER

    7,000,000

    7

    SOLE DISPOSITIVE POWER

    0

    8

    SHARED DISPOSITIVE POWER

    7,000,000

    9

    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

    7,000,000

    10 CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES ¨
    11

    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)

    1.59%

    12

    TYPE OF REPORTING PERSON

    PN

             

     

     

     

     

    CUSIP No. G7709Q10413G/APage 3 of 10 Pages

     

     

    1

    NAME OF REPORTING PERSON

    Adage Capital Partners GP, L.L.C.

    2 CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP

    (a) ¨

    (b) ¨

    3 SEC USE ONLY
    4

    CITIZENSHIP OR PLACE OF ORGANIZATION

    Delaware

    NUMBER OF
    SHARES
    BENEFICIALLY
    OWNED BY
    EACH
    REPORTING
    PERSON WITH:
    5

    SOLE VOTING POWER

    0

    6

    SHARED VOTING POWER

    7,000,000

    7

    SOLE DISPOSITIVE POWER

    0

    8

    SHARED DISPOSITIVE POWER

    7,000,000

    9

    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

    7,000,000

    10 CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES ¨
    11

    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)

    1.59%

    12

    TYPE OF REPORTING PERSON

    OO

             

     

     

     

    CUSIP No. G7709Q10413G/APage 4 of 10 Pages

     

     

    1

    NAME OF REPORTING PERSON

    Adage Capital Advisors, L.L.C.

    2 CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP

    (a) ¨

    (b) ¨

    3 SEC USE ONLY
    4

    CITIZENSHIP OR PLACE OF ORGANIZATION

    Delaware

    NUMBER OF
    SHARES
    BENEFICIALLY
    OWNED BY
    EACH
    REPORTING
    PERSON WITH:
    5

    SOLE VOTING POWER

    0

    6

    SHARED VOTING POWER

    7,000,000

    7

    SOLE DISPOSITIVE POWER

    0

    8

    SHARED DISPOSITIVE POWER

    7,000,000

    9

    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

    7,000,000

    10 CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES ¨
    11

    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)

    1.59%

    12

    TYPE OF REPORTING PERSON

    OO

             

     

     

     

    CUSIP No. G7709Q10413G/APage 5 of 10 Pages

     

     

    1

    NAME OF REPORTING PERSON

    Robert Atchinson

    2 CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP

    (a) ¨

    (b) ¨

    3 SEC USE ONLY
    4

    CITIZENSHIP OR PLACE OF ORGANIZATION

    United States

    NUMBER OF
    SHARES
    BENEFICIALLY
    OWNED BY
    EACH
    REPORTING
    PERSON WITH:
    5

    SOLE VOTING POWER

    0

    6

    SHARED VOTING POWER

    7,000,000

    7

    SOLE DISPOSITIVE POWER

    0

    8

    SHARED DISPOSITIVE POWER

    7,000,000

    9

    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

    7,000,000

    10 CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES ¨
    11

    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)

    1.59%

    12

    TYPE OF REPORTING PERSON

    IN

             

     

     

     

     

    CUSIP No. G7709Q10413G/APage 6 of 10 Pages

     

     

    1

    NAME OF REPORTING PERSON

    Phillip Gross

    2 CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP

    (a) ¨

    (b) ¨

    3 SEC USE ONLY
    4

    CITIZENSHIP OR PLACE OF ORGANIZATION

    United States

    NUMBER OF
    SHARES
    BENEFICIALLY
    OWNED BY
    EACH
    REPORTING
    PERSON WITH:
    5

    SOLE VOTING POWER

    0

    6

    SHARED VOTING POWER

    7,000,000

    7

    SOLE DISPOSITIVE POWER

    0

    8

    SHARED DISPOSITIVE POWER

    7,000,000

    9

    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

    7,000,000

    10 CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES ¨
    11

    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)

    1.59%

    12

    TYPE OF REPORTING PERSON

    IN

             

     

     

     

     

    CUSIP No. G7709Q10413G/APage 7 of 10 Pages

     

     

     

    Item 1(a). NAME OF ISSUER
      The name of the issuer is Royalty Pharma plc (the "Company").

     

    Item 1(b). ADDRESS OF ISSUER'S PRINCIPAL EXECUTIVE OFFICES
      The Company's principal executive offices are located at 110 East 59th Street, New York, New York 10022.

     

    Item 2(a). NAME OF PERSON FILING
      This statement is filed by:

     

      (i) Adage Capital Partners, L.P., a Delaware limited partnership ("ACP") with respect to the Class A Ordinary Shares directly owned by it;
       
      (ii) Adage Capital Partners GP, L.L.C., a limited liability company organized under the laws of the State of Delaware ("ACPGP"), as general partner of ACP with respect to the Class A Ordinary Shares directly owned by ACP;
       
      (iii) Adage Capital Advisors, L.L.C., a limited liability company organized under the laws of the State of Delaware ("ACA"), as managing member of ACPGP, general partner of ACP, with respect to the Class A Ordinary Shares directly owned by ACP;
       
      (iv) Robert Atchinson ("Mr. Atchinson"), as managing member of ACA, managing member of ACPGP, general partner of ACP with respect to the Class A Ordinary Shares directly owned by ACP; and
       
      (v) Phillip Gross ("Mr. Gross"), as managing member of ACA, managing member of ACPGP, general partner of ACP with respect to the Class A Ordinary Shares directly owned by ACP.

     

      The foregoing persons are hereinafter sometimes collectively referred to as the "Reporting Persons."  Any disclosures herein with respect to persons other than the Reporting Persons are made on information and belief after making inquiry to the appropriate party.
       
      The filing of this statement should not be construed in and of itself as an admission by any Reporting Person as to beneficial ownership of the securities reported herein.

     

    Item 2(b). ADDRESS OF PRINCIPAL BUSINESS OFFICE OR, IF NONE, RESIDENCE
      The address of the business office of each of the Reporting Persons is 200 Clarendon Street, 52nd Floor, Boston, Massachusetts 02116.

     

    Item 2(c). CITIZENSHIP
      ACP is a limited partnership organized under the laws of the State of Delaware.  ACPGP and ACA are limited liability companies organized under the laws of the State of Delaware.  Messrs. Gross and Atchinson are citizens of the United States.

     

     

    CUSIP No. G7709Q10413G/APage 8 of 10 Pages

     

     

    Item 2(d). TITLE OF CLASS OF SECURITIES
      Class A Ordinary Shares, par value $0.0001 per share (the "Class A Ordinary Shares").

     

    Item 2(e). CUSIP NUMBER
      G7709Q104

     

    Item 3. IF THIS STATEMENT IS FILED PURSUANT TO Rules 13d-1(b), OR 13d-2(b) OR (c), CHECK WHETHER THE PERSON FILING IS A:
      (a) ¨ Broker or dealer registered under Section 15 of the Act;
      (b) ¨ Bank as defined in Section 3(a)(6) of the Act;
      (c) ¨ Insurance company as defined in Section 3(a)(19) of the Act;
      (d) ¨ Investment company registered under Section 8 of the Investment Company Act of 1940;
      (e) ¨ An investment adviser in accordance with Rule 13d-1(b)(1)(ii)(E);
      (f) ¨

    An employee benefit plan or endowment fund in accordance with Rule 13d-1(b)(1)(ii)(F);

     

      (g) ¨

    A parent holding company or control person in accordance with Rule 13d-1(b)(1)(ii)(G);

     

      (h) ¨

    A savings association as defined in Section 3(b) of the Federal Deposit Insurance Act;

     

      (i) ¨

    A church plan that is excluded from the definition of an investment company under Section 3(c)(14) of the Investment Company Act;

     

      (j) ¨ A non-U.S. institution in accordance with Rule 13d-1(b)(1)(ii)(J);
      (k) ¨ Group, in accordance with Rule 13d-1(b)(1)(ii)(K).

     

     

    If filing as a non-U.S. institution in accordance with Rule 13d-1(b)(1)(ii)(J), please

    specify the type of institution: Not applicable.

     

    Item 4. OWNERSHIP
      A. Adage Capital Partners, L.P., Adage Capital Partners GP, L.L.C. and Adage Capital Advisors, L.L.C.
        (a) Amount beneficially owned:  7,000,000
        (b) Percent of class:  1.59%.  The percentage set forth in this Schedule 13G/A is calculated based upon a total of 441,104,204 Class A Ordinary Shares outstanding as of November 4, 2022, as reported in the Company's Quarterly Report on Form 10-Q for the quarterly period ended September 30, 2022 filed with the Securities and Exchange Commission on November 8, 2022.
        (c) (i) Sole power to vote or direct the vote:  0
          (ii) Shared power to vote or direct the vote: 7,000,000
          (iii) Sole power to dispose or direct the disposition:  0
          (iv) Shared power to dispose or direct the disposition of:  7,000,000

     

     

    CUSIP No. G7709Q10413G/APage 9 of 10 Pages

     

    ACP has the power to dispose of and the power to vote the Class A Ordinary Shares beneficially owned by it, which power may be exercised by its general partner, ACPGP.  ACA, as managing member of ACPGP, directs ACPGP's operations. Neither ACPGP nor ACA directly own any Class A Ordinary Shares.  By reason of the provisions of Rule 13d-3 of the Securities Exchange Act of 1934 (the "Act"), ACPGP and ACA may be deemed to beneficially own the shares owned by ACP.

     

      B. Robert Atchinson and Phillip Gross
        (a) Amount beneficially owned:  7,000,000
        (b) Percent of class:  1.59%
        (c) (i) Sole power to vote or direct the vote:  0
          (ii) Shared power to vote or direct the vote:  7,000,000
          (iii) Sole power to dispose or direct the disposition:  0
          (iv) Shared power to dispose or direct the disposition:  7,000,000

     

    Messrs. Atchinson and Gross, as managing members of ACA, have shared power to vote the Class A Ordinary Shares beneficially owned by ACP.  Neither Mr. Atchinson nor Mr. Gross directly own any Class A Ordinary Shares.  By reason of the provisions of Rule 13d-3 of the Act, each may be deemed to beneficially own the Class A Ordinary Shares beneficially owned by ACP.

     

    Item 5. OWNERSHIP OF FIVE PERCENT OR LESS OF A CLASS
      If this statement is being filed to report the fact that as of the date hereof the reporting person has ceased to be the beneficial owner of more than five percent of the class of securities, check the following: ý

     

    Item 6. OWNERSHIP OF MORE THAN FIVE PERCENT ON BEHALF OF ANOTHER PERSON
      Not applicable.

     

    Item 7. IDENTIFICATION AND CLASSIFICATION OF THE SUBSIDIARY WHICH ACQUIRED THE SECURITY BEING REPORTED ON BY THE PARENT HOLDING COMPANY OR CONTROL PERSON
      Not applicable.

     

    Item 8. IDENTIFICATION AND CLASSIFICATION OF MEMBERS OF THE GROUP
      Not applicable.

     

    Item 9. NOTICE OF DISSOLUTION OF GROUP
      Not applicable.

     

    Item 10. CERTIFICATION  
      Each of the Reporting Persons hereby makes the following certification:
       
      By signing below each Reporting Person certifies that, to the best of his or its knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect.

     

     

    CUSIP No. G7709Q10413G/APage 10 of 10 Pages

    SIGNATURES

    After reasonable inquiry and to the best of his or its knowledge and belief, each of the undersigned certifies that the information set forth in this statement is true, complete and correct.
       
    DATE:  February 9, 2023  
       
    ADAGE CAPITAL PARTNERS, L.P.  
    By:  Adage Capital Partners GP, L.L.C.,  
    its general partner  
       
    By:  Adage Capital Advisors, L.L.C.,  
    its managing member  
       
    /s/ Robert Atchinson  
    Name:  Robert Atchinson  
    Title: Managing Member  
       
    ADAGE CAPITAL PARTNERS GP, L.L.C.  
    By:  Adage Capital Advisors, L.L.C.,  
    its managing member  
       
    /s/ Robert Atchinson  
    Name:  Robert Atchinson  
    Title: Managing Member  
       
    ADAGE CAPITAL ADVISORS, L.L.C.  
       
    /s/ Robert Atchinson  
    Name:  Robert Atchinson  
    Title: Managing Member  
       
    ROBERT ATCHINSON  
       
    /s/ Robert Atchinson  
    ROBERT ATCHINSON, individually  
       
    PHILLIP GROSS  
       
    /s/ Phillip Gross  
    PHILLIP GROSS, individually  

     

    Get the next $RPRX alert in real time by email

    Crush Q3 2025 with the Best AI Executive Assistant

    Stay ahead of the competition with Tailforce.ai - your AI-powered business intelligence partner.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Tailforce.ai

    Recent Analyst Ratings for
    $RPRX

    DatePrice TargetRatingAnalyst
    5/16/2025$51.00Overweight
    Morgan Stanley
    6/3/2024$28.00Buy → Neutral
    UBS
    6/14/2022$47.00Buy
    UBS
    5/13/2022$53.00Sector Outperform
    Scotiabank
    4/27/2022$56.00Buy
    Goldman
    4/14/2022$50.00Neutral → Overweight
    JP Morgan
    4/6/2022$48.00Overweight
    Morgan Stanley
    10/29/2021$50.00Neutral → Buy
    Citigroup
    More analyst ratings

    $RPRX
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Royalty Pharma and Revolution Medicines Enter Into Funding Agreements for Up to $2 Billion

      Up to $1.25 billion ($250 million upfront) of synthetic royalty funding and up to $750 million in secured debt Innovative partnership enables Revolution Medicines to retain control over pipeline development and global commercialization of daraxonrasib Highlights Royalty Pharma's unique ability to provide capital at scale to help leading companies achieve their strategic goalsDaraxonrasib, in Phase 3 development for pancreatic cancer and non-small cell lung cancer, would be the first targeted therapy to inhibit all major forms of RAS, one of the most common drivers of human cancers NEW YORK, June 24, 2025 (GLOBE NEWSWIRE) -- Royalty Pharma plc (NASDAQ:RPRX) today announced a $2 billi

      6/24/25 7:05:00 AM ET
      $RPRX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Royalty Pharma to Present at the Goldman Sachs 46th Annual Global Healthcare Conference

      NEW YORK, June 04, 2025 (GLOBE NEWSWIRE) -- Royalty Pharma plc (NASDAQ:RPRX) today announced that it will participate in a fireside chat at the Goldman Sachs 46th Annual Global Healthcare Conference on Tuesday, June 10, 2025 at 2:00 p.m. ET. The webcast will be accessible from Royalty Pharma's "Events" page at https://www.royaltypharma.com/investors/events/. The webcast will also be archived for a minimum of thirty days. About Royalty Pharma Founded in 1996, Royalty Pharma is the largest buyer of biopharmaceutical royalties and a leading funder of innovation across the biopharmaceutical industry, collaborating with innovators from academic institutions, research hospitals and non-profi

      6/4/25 4:15:00 PM ET
      $RPRX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Royalty Pharma Completes the Acquisition of Its External Manager

      NEW YORK, May 16, 2025 (GLOBE NEWSWIRE) -- Royalty Pharma plc (NASDAQ:RPRX) today announced that it has successfully closed the acquisition of its external manager, RP Management, LLC ("RP Management"). The acquisition received overwhelming support from Royalty Pharma's shareholders, with 99.9% of votes cast in favor of the transaction. "The completion of the internalization marks an exciting new chapter for Royalty Pharma," said Pablo Legorreta, founder and Chief Executive Officer. "It reinforces our commitment to transparency, accountability and long-term growth, while better positioning us to fund the significant capital needs and exciting innovation happening in the life sciences indu

      5/16/25 4:30:00 PM ET
      $RPRX
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $RPRX
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Director Fernandez Henry A was granted 1,064 units of Class A Ordinary Shares, increasing direct ownership by 2% to 65,324 units (SEC Form 4)

      4 - Royalty Pharma plc (0001802768) (Issuer)

      6/30/25 5:06:05 PM ET
      $RPRX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Director Bassler Bonnie L was granted 1,064 units of Class A Ordinary Shares, increasing direct ownership by 2% to 71,118 units (SEC Form 4)

      4 - Royalty Pharma plc (0001802768) (Issuer)

      6/30/25 5:04:29 PM ET
      $RPRX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 4 filed by EVP & Vice Chairman Hite Christopher

      4 - Royalty Pharma plc (0001802768) (Issuer)

      5/20/25 4:54:54 PM ET
      $RPRX
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $RPRX
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Morgan Stanley initiated coverage on Royalty Pharma with a new price target

      Morgan Stanley initiated coverage of Royalty Pharma with a rating of Overweight and set a new price target of $51.00

      5/16/25 8:05:49 AM ET
      $RPRX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Royalty Pharma downgraded by UBS with a new price target

      UBS downgraded Royalty Pharma from Buy to Neutral and set a new price target of $28.00

      6/3/24 9:17:33 AM ET
      $RPRX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • UBS resumed coverage on Royalty Pharma with a new price target

      UBS resumed coverage of Royalty Pharma with a rating of Buy and set a new price target of $47.00

      6/14/22 7:27:46 AM ET
      $RPRX
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $RPRX
    SEC Filings

    See more
    • SEC Form SCHEDULE 13D filed by Royalty Pharma plc

      SCHEDULE 13D - Royalty Pharma plc (0001802768) (Subject)

      5/23/25 5:05:26 PM ET
      $RPRX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Royalty Pharma plc filed SEC Form 8-K: Completion of Acquisition or Disposition of Assets, Entry into a Material Definitive Agreement, Creation of a Direct Financial Obligation

      8-K - Royalty Pharma plc (0001802768) (Filer)

      5/19/25 5:22:18 PM ET
      $RPRX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form S-8 filed by Royalty Pharma plc

      S-8 - Royalty Pharma plc (0001802768) (Filer)

      5/16/25 4:24:25 PM ET
      $RPRX
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $RPRX
    Leadership Updates

    Live Leadership Updates

    See more
    • Royalty Pharma Appoints Vlad Coric, M.D. to the Company's Board of Directors

      NEW YORK, April 08, 2025 (GLOBE NEWSWIRE) -- Royalty Pharma plc (NASDAQ:RPRX) today announced the appointment of Vlad Coric, M.D. to the company's Board of Directors, effective immediately. Vlad Coric is the Chairman and Chief Executive Officer of Biohaven, a biopharmaceutical company focused on the discovery, development and commercialization of life-changing treatments in key therapeutic areas including neuroscience, immunology and oncology. "I am excited to announce that we are strengthening our Board with the appointment of Vlad Coric," said Pablo Legorreta, founder and Chief Executive Officer of Royalty Pharma. "Vlad's entrepreneurial approach and outstanding leadership skills, hon

      4/8/25 4:15:00 PM ET
      $RPRX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Royalty Pharma Appoints Molly Sawaya as Executive Vice President, Head of Human Capital

      NEW YORK, July 24, 2024 (GLOBE NEWSWIRE) -- Royalty Pharma plc (NASDAQ:RPRX) today announced the appointment of Molly Sawaya as Executive Vice President, Head of Human Capital. Molly joins Royalty Pharma from Hudson Bay Capital, where she was a Managing Director and Head of Colleague Experience, responsible for designing and delivering the firm's Human Resources (HR) agenda, including onboarding, colleague engagement, professional development, compensation and benefits. Previously, Molly held a number of global HR roles of increasing responsibility at QBE Insurance Group, Perpetual Limited and National Australia Bank. Molly received her Bachelor of Arts and Master of Applied Science deg

      7/24/24 8:30:00 AM ET
      $RPRX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Royalty Pharma Appoints Eric Schneider as Chief Technology Officer

      NEW YORK, Sept. 21, 2023 (GLOBE NEWSWIRE) -- Royalty Pharma plc (NASDAQ:RPRX) today announced the appointment of Eric Schneider as Senior Vice President, Chief Technology Officer. Eric will also join Royalty Pharma's Senior Leadership Committee. Eric joins Royalty Pharma from Verisk, a global leader in data-driven analytic insights and solutions, where he was a Senior Vice President, Chief Data Officer and Chief Technology Officer, and a member of the Executive Leadership Team. During his tenure at Verisk, he led their migration to the cloud, mainframe modernization strategy and Data Governance and Data Strategy Team. Prior to Verisk, Mr. Schneider held senior IT leadership roles at Moody

      9/21/23 8:25:00 AM ET
      $RPRX
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $RPRX
    Financials

    Live finance-specific insights

    See more
    • Royalty Pharma and Revolution Medicines Enter Into Funding Agreements for Up to $2 Billion

      Up to $1.25 billion ($250 million upfront) of synthetic royalty funding and up to $750 million in secured debt Innovative partnership enables Revolution Medicines to retain control over pipeline development and global commercialization of daraxonrasib Highlights Royalty Pharma's unique ability to provide capital at scale to help leading companies achieve their strategic goalsDaraxonrasib, in Phase 3 development for pancreatic cancer and non-small cell lung cancer, would be the first targeted therapy to inhibit all major forms of RAS, one of the most common drivers of human cancers NEW YORK, June 24, 2025 (GLOBE NEWSWIRE) -- Royalty Pharma plc (NASDAQ:RPRX) today announced a $2 billi

      6/24/25 7:05:00 AM ET
      $RPRX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Royalty Pharma Completes the Acquisition of Its External Manager

      NEW YORK, May 16, 2025 (GLOBE NEWSWIRE) -- Royalty Pharma plc (NASDAQ:RPRX) today announced that it has successfully closed the acquisition of its external manager, RP Management, LLC ("RP Management"). The acquisition received overwhelming support from Royalty Pharma's shareholders, with 99.9% of votes cast in favor of the transaction. "The completion of the internalization marks an exciting new chapter for Royalty Pharma," said Pablo Legorreta, founder and Chief Executive Officer. "It reinforces our commitment to transparency, accountability and long-term growth, while better positioning us to fund the significant capital needs and exciting innovation happening in the life sciences indu

      5/16/25 4:30:00 PM ET
      $RPRX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Royalty Pharma Announces Shareholder Approval of its External Manager Acquisition

      Received overwhelming shareholder approval with 99.9% of votes cast in favorSimplified structure benefits shareholders through strengthened shareholder alignment, enhanced governance, significant cash savings and increased economic return on investments Significant annual cash savings of greater than $100 million in 2026 growing to over $175 million in 2030, with cumulative savings of more than $1.6 billion over ten yearsRoyalty Pharma's diversified royalty portfolio to be combined with intellectual capital and investment platform of the Manager to advance shareholder value creation NEW YORK, May 12, 2025 (GLOBE NEWSWIRE) -- Royalty Pharma plc (NASDAQ:RPRX) today announced that sharehold

      5/12/25 4:15:00 PM ET
      $RPRX
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $RPRX
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • Amendment: SEC Form SC 13G/A filed by Royalty Pharma plc

      SC 13G/A - Royalty Pharma plc (0001802768) (Subject)

      11/8/24 3:15:49 PM ET
      $RPRX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Amendment: SEC Form SC 13D/A filed by Royalty Pharma plc

      SC 13D/A - Royalty Pharma plc (0001802768) (Subject)

      7/29/24 4:30:11 PM ET
      $RPRX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13G/A filed by Royalty Pharma plc (Amendment)

      SC 13G/A - Royalty Pharma plc (0001802768) (Subject)

      2/13/24 10:17:30 AM ET
      $RPRX
      Biotechnology: Pharmaceutical Preparations
      Health Care